Abstract
Numerous solid tumors and hematologic malignancies acquire resistance to apoptosis-inducing chemotherapeutic drugs by downregulating the key effector caspase-3. These cells rely on caspase-7 to execute the apoptotic program, yet binding with XIAP constitutively inhibits active caspase-7 (p19/p12-CASP7). In this issue, Lin et al. describe how a newly synthesized drug is able to disrupt the XIAP:p19/p12-CASP7 complex and induce apoptosis in caspase-3-deficient cancer cells in vitro and in vivo. As this compound appears to exhibit minimal toxicity on normal tissues, it may represent a promising therapeutic agent to help treat caspase-3-deficient tumors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3706-3708 |
| Number of pages | 3 |
| Journal | Journal of Clinical Investigation |
| Volume | 123 |
| Issue number | 9 |
| DOIs |
|
| State | Published - Sep 3 2013 |
ASJC Scopus subject areas
- Medicine(all)
Fingerprint Dive into the research topics of 'Unshackling caspase-7 for cancer therapy'. Together they form a unique fingerprint.
Cite this
Guicciardi, M. E., & Gores, G. J. (2013). Unshackling caspase-7 for cancer therapy. Journal of Clinical Investigation, 123(9), 3706-3708. https://doi.org/10.1172/JCI71440